LITS

Lite Strategy, Inc. (LITS) 10-K Summary

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended June 30, 2025. On September 10, 2025, the company changed its name from MEI Pharma, Inc. to Lite Strategy, Inc. and its ticker symbol to LITS. The company has fundamentally pivoted from a clinical-stage pharmaceutical developer to a digital asset treasury company. Following the discontinuation of its clinical drug development programs in July 2024, the company implemented a Litecoin Treasury Strategy in August 2025, deploying net proceeds from a recent financing to acquire Litecoin (LTC) tokens as its primary reserve asset.

Key Financial Metrics

Note: The filing text does not provide specific margin percentages due to the absence of revenue in the current period and the non-recurring nature of prior year revenue.

Material Changes vs. Prior Period

• Revenue Collapse: Revenue dropped to zero in FY2025 compared to $65.3 million in FY2024. The prior year revenue was driven by the recognition of deferred revenue from the terminated Kyowa Kirin (KKC) collaboration agreement, which was fully recognized in FY2024.
• Expense Reduction: Total operating expenses decreased by approximately $33.3 million (65.4%). Research and Development (R&D) expenses fell 76.3% to $3.9 million due to the cessation of clinical trials for voruciclib and zandelisib. General and Administrative (G&A) expenses decreased 41.9% to $13.5 million, driven by workforce reductions and lease terminations.
• Impairment Reversal: The company recorded a $10.9 million impairment of long-lived assets in FY2024 related to lease termination and furniture disposal. No such impairment occurred in FY2025.
• Strategic Pivot: The company shifted from oncology drug development to a cryptocurrency treasury model, acquiring Litecoin with proceeds from a subsequent financing.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Litecoin Treasury Strategy: In July 2025, the company closed a $100.0 million Private Investment in Public Equity (PIPE) transaction, raising net proceeds of approximately $92.1 million. These funds were deployed to acquire Litecoin tokens. The company anticipates potential Litecoin mining activities.
• Drug Pipeline: Clinical development for voruciclib and zandelisib has been discontinued. The company is assessing pre-clinical activities for these assets but has no active clinical trials.
• Liquidity: Management believes current cash balances are sufficient to fund operations for at least the next 12 months.

Risks and Contingencies:

• Cryptocurrency Volatility: The value of the company's primary asset (Litecoin) is subject to high volatility. The filing notes Litecoin traded between $50.43 and $146.61 in the 12 months ended July 3, 2025.
• Regulatory Uncertainty: There is a risk that Litecoin could be classified as a security, which could subject the company to the Investment Company Act of 1940 if Litecoin holdings exceed 40% of total assets.
• Cybersecurity: The company faces risks of security breaches, cyberattacks, or loss of private keys that could result in the total loss of its Litecoin holdings.
• Capital Requirements: If the company resumes drug development, it will require significant additional capital. There is no assurance that future financing will be available.

Investor Verification Checklist

• Verify Litecoin Holdings: Confirm the exact quantity and current market value of Litecoin acquired with the PIPE proceeds, as this now represents the majority of the company's asset base.
• Review PIPE Terms: Examine the specific terms of the $100 million PIPE, including the exercise prices of pre-funded warrants and the dilution impact of the 3.07 million warrants issued to advisors.
• Assess Regulatory Status: Monitor SEC and CFTC guidance regarding the classification of Litecoin to evaluate the risk of the company being deemed an "investment company."
• Check Cash Runway: Verify the current cash balance against the $18.0 million reported as of June 30, 2025, to confirm the 12-month liquidity runway remains valid given the new treasury strategy.
• Monitor Stock Price vs. Exercise Prices: Compare the current stock price to the weighted-average exercise price of outstanding options ($32.90) and warrants ($4.10) to assess potential dilution or upside.